These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

586 related items for PubMed ID: 22172822

  • 1. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
    Pliszczynski J, Kahan BD.
    Transplant Proc; 2011 Dec; 43(10):3657-68. PubMed ID: 22172822
    [Abstract] [Full Text] [Related]

  • 2. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 3. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.
    Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J, Russ G, Grinyó JM, Stallone G, Hartmann A, Pinto JR, Chapman J, Burke JT, Brault Y, Neylan JF, Rapamune Maintenance Regimen Study Group.
    Transpl Int; 2005 Jan 15; 18(1):22-8. PubMed ID: 15612979
    [Abstract] [Full Text] [Related]

  • 4. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.
    Morales JM, Hartmann A, Walker R, Arns W, Senatorski G, Grinyó JM, Shoker A, Wilczek H, Jamieson NV, Lelong M, Brault Y, Burke JT, Scarola JA, Rapamune Maintenance Regimen Study Group.
    Transplant Proc; 2009 Jan 15; 41(6):2339-44. PubMed ID: 19715914
    [Abstract] [Full Text] [Related]

  • 5. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.
    Morales JM, Campistol JM, Kreis H, Mourad G, Eris J, Schena FP, Grinyo JM, Nanni G, Andres A, Castaing N, Brault Y, Burke JT.
    Transplant Proc; 2005 Mar 15; 37(2):693-6. PubMed ID: 15848504
    [Abstract] [Full Text] [Related]

  • 6. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
    Oberbauer R, Kreis H, Johnson RW, Mota A, Claesson K, Ruiz JC, Wilczek H, Jamieson N, Henriques AC, Paczek L, Chapman J, Burke JT, Rapamune Maintenance Regimen Study Group.
    Transplantation; 2003 Jul 27; 76(2):364-70. PubMed ID: 12883194
    [Abstract] [Full Text] [Related]

  • 7. Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years.
    Legendre C, Brault Y, Morales JM, Oberbauer R, Altieri P, Riad H, Mahony J, Messina M, Pussell B, Martínez JG, Lelong M, Burke JT, Neylan JF, Rapamune Maintenance Regimen Study Group.
    Clin Transplant; 2007 Jul 27; 21(3):330-6. PubMed ID: 17488381
    [Abstract] [Full Text] [Related]

  • 8. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 9. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK, Wu FL, Lai IR, Lee CY, Hu RH, Lee PH.
    Int J Artif Organs; 2009 Jun 27; 32(6):371-80. PubMed ID: 19670189
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the safety and efficacy of cyclosporine minimization versus cyclosporine elimination in de novo renal allograft patients receiving sirolimus.
    Tedesco-Silva H, Garcia VD, Contieri FL, De Boni Monteiro de Carvalho D, Noronha IL, Gonçalves RT, de Paula FJ, Abbud-Filho M, Manfro RC, David-Neto E, Alfieri F, Ikehara E, Jiang Q, Tai SS, Medina-Pestana JO.
    Transplant Proc; 2010 Jun 27; 42(5):1659-66. PubMed ID: 20620495
    [Abstract] [Full Text] [Related]

  • 11. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine.
    Romagnoli J, Citterio F, Nanni G, Favi E, Tondolo V, Spagnoletti G, Salerno MP, Castagneto M.
    Transplant Proc; 2006 May 27; 38(4):1034-6. PubMed ID: 16757255
    [Abstract] [Full Text] [Related]

  • 12. Statins benefit outcomes of renal transplant recipients on a sirolimus-cyclosporine regimen.
    Lisik W, Schoenberg L, Lasky RE, Kahan BD.
    Transplant Proc; 2007 Dec 27; 39(10):3086-92. PubMed ID: 18089328
    [Abstract] [Full Text] [Related]

  • 13. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM, Carlos CM, Cabanayan-Casasola CB, Danguilan RA.
    Transplant Proc; 2012 Jan 27; 44(1):154-60. PubMed ID: 22310603
    [Abstract] [Full Text] [Related]

  • 14. The combination of sirolimus and cyclosporine does not delay initial renal graft function recovery.
    Hsu HJ, Tian YC, Chen YC, Lai BC, Fang JT, Yang CW, Wu MS.
    Ren Fail; 2008 Jan 27; 30(3):303-6. PubMed ID: 18350450
    [Abstract] [Full Text] [Related]

  • 15. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
    Cibrik D, Silva HT, Vathsala A, Lackova E, Cornu-Artis C, Walker RG, Wang Z, Zibari GB, Shihab F, Kim YS.
    Transplantation; 2013 Apr 15; 95(7):933-42. PubMed ID: 23422495
    [Abstract] [Full Text] [Related]

  • 16. Three-year health-related quality-of-life outcomes for sirolimus-treated kidney transplant patients after elimination of cyclosporine.
    Russ G, Jamieson N, Oberbauer R, Arias M, Murgia MG, Blancho G, Sato R, Stoeckl M, Revicki DA.
    Transpl Int; 2007 Oct 15; 20(10):875-83. PubMed ID: 17854445
    [Abstract] [Full Text] [Related]

  • 17. New approaches to de novo immunosuppression and steroid elimination.
    Lebranchu Y.
    Transplant Proc; 2009 Oct 15; 41(6 Suppl):S39-41. PubMed ID: 19651295
    [Abstract] [Full Text] [Related]

  • 18. Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function.
    Friend P, Russ G, Oberbauer R, Murgia MG, Tufveson G, Chapman J, Blancho G, Mota A, Grandaliano G, Campistol JM, Brault Y, Burke JT, Rapamune Maintenance Regimen (RMR) Study Group.
    Transpl Int; 2007 Sep 15; 20(9):754-60. PubMed ID: 17565578
    [Abstract] [Full Text] [Related]

  • 19. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial.
    Salvadori M, Scolari MP, Bertoni E, Citterio F, Rigotti P, Cossu M, Dal Canton A, Tisone G, Albertazzi A, Pisani F, Gubbiotti G, Piredda G, Busnach G, Sparacino V, Goepel V, Messa P, Berloco P, Montanaro D, Veroux P, Federico S, Bartezaghi M, Corbetta G, Ponticelli C.
    Transplantation; 2009 Nov 27; 88(10):1194-202. PubMed ID: 19935373
    [Abstract] [Full Text] [Related]

  • 20. Primary immunosuppression and outcome differences after heart transplantation: tacrolimus versus cyclosporine.
    Castel MA, Farrero M, Vallejos I, Cardona M, Regueiro A, Pérez-Villa F.
    Transplant Proc; 2011 Nov 27; 43(6):2244-6. PubMed ID: 21839245
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.